Show simple item record

dc.contributor.authorPriddy, Sarah E.
dc.contributor.authorHoward, Matthew O.
dc.contributor.authorHanley, Adam W.
dc.contributor.authorRiquino, Michael R.
dc.contributor.authorFriberg-Felsted, Katarina
dc.contributor.authorGarland, Eric L.
dc.date.accessioned2019-09-18T15:01:12Z
dc.date.available2019-09-18T15:01:12Z
dc.date.issued2018-11-16
dc.identifier.citationPriddy, S.E., Howard, M.O., Hanley, A.W., Riquino, M.R., Friberg-Felsted, K., & Garland, E.L. (2018). Mindfulness meditation in the treatment of substance use disorders and preventing future relapse: Neurocognitive mechanisms and clinical implications. Substance Abuse and Rehabilitation, 9, 103-114. doi: 10.2147/SAR.S145201en_US
dc.identifier.urihttp://hdl.handle.net/1808/29602
dc.description.abstractSubstance use disorders (SUDs) are a pervasive public health problem with deleterious consequences for individuals, families, and society. Furthermore, SUD intervention is complicated by the continuous possibility of relapse. Despite decades of research, SUD relapse rates remain high, underscoring the need for more effective treatments. Scientific findings indicate that SUDs are driven by dysregulation of neural processes underlying reward learning and executive functioning. Emerging evidence suggests that mindfulness training can target these neurocognitive mechanisms to produce significant therapeutic effects on SUDs and prevent relapse. The purpose of this manuscript is to review the cognitive, affective, and neural mechanisms underlying the effects of mindfulness-based interventions (MBIs) on SUDs. We discuss the etiology of addiction and neurocognitive processes related to the development and maintenance of SUDs. We then explore evidence supporting use of MBIs for intervening in SUDs and preventing relapse. Finally, we provide clinical recommendations about how these therapeutic mechanisms might be applied to intervening in SUDs and preventing relapse.en_US
dc.description.sponsorshipNational Institute of Health (NIH) award to ELG (R01DA042033)en_US
dc.publisherDove Medical Pressen_US
dc.rights© 2018 Priddy et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. https://www.dovepress.com/terms.phpen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/en_US
dc.subjectAddictionen_US
dc.subjectMindfulnessen_US
dc.subjectRewarden_US
dc.subjectRelapseen_US
dc.subjectSubstance use disordersen_US
dc.titleMindfulness meditation in the treatment of substance use disorders and preventing future relapse: neurocognitive mechanisms and clinical implicationsen_US
dc.typeArticleen_US
kusw.kuauthorRiquino, Michael R.
kusw.kudepartmentSocial Welfareen_US
dc.identifier.doi10.2147/SAR.S145201en_US
dc.identifier.orcidhttps://orcid.org/0000-0001-5052-541Xen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-0373-2421en_US
kusw.oaversionScholarly/refereed, publisher versionen_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.rights.accessrightsopenAccessen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2018 Priddy et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. https://www.dovepress.com/terms.php
Except where otherwise noted, this item's license is described as: © 2018 Priddy et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. https://www.dovepress.com/terms.php